Deutsche Bank

Deutsche Bank’s AEON Biopharma AEON Stock Holding History

Deutsche Bank’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-752	Closed	-$549K	–	3801
2023 Q1	$549K	Buy	+752	New	+$546K	﹤0.01%	2440

Other funds holding AEON

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Walleye Capital

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Deutsche Bank's AEON Position: Q2 2023 in Review

Deutsche Bank sold out of AEON Biopharma (AEON) in Q2 2023, closing a stake of 752 shares — an estimated $549K sold.

Deutsche Bank first reported a position in AEON in Q1 2023 and held it in 1 quarter. The position peaked at $549K in Q1 2023. 17 funds tracked by Wall St. Rank hold AEON as of Q2 2023.

Deutsche Bank reported no remaining AEON Biopharma position as of Q2 2023 after selling out during the quarter.
Deutsche Bank sold 752 AEON Biopharma shares in Q2 2023, an estimated $549K.
Deutsche Bank first reported a position in AEON Biopharma in Q1 2023 and held it in 1 quarter.
Deutsche Bank's AEON Biopharma position peaked at $549K in Q1 2023.
17 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2023.

Based on Deutsche Bank's 13F filing for Q2 2023, filed 14 Aug 2023.